Skip to content
Open access

Unraveling the molecular Nexus of Alzheimer’s Disease and HIV encephalitis: The role of cellular senescence and transcriptional regulation

Aug 2026 · PLoS ONE · Vol 21, pp. e0355548 - e0355548 · 0 citations · 47 references
Medicine

TL;DR

Computational findings indicate FOXO3 transcriptional regulatory activity in neurodegeneration in Alzheimer's disease and HIV-associated neurocognitive disorder and blood-based detection offers non-invasive diagnostic potential.

Abstract

Alzheimer’s disease (AD) and HIV-associated neurocognitive disorder (HAND) share progressive cognitive decline. Their common molecular mechanisms remain poorly understood. Current therapeutic approaches lack effective biomarkers for early diagnosis and intervention. We integrated transcriptomic profiles from multiple independent cohorts across brain tissues and blood. We systematically evaluated diagnostic performance using machine learning algorithms including Random Forest, Support Vector Machine, and XGBoost. Notably, FOXO3 emerged as the top cross-disease biomarker. FOXO3 achieved diagnostic accuracy in AD temporal cortex (area under the curve [AUC] = 0.922, 95% CI: 0.885–0.959). FOXO3 showed diagnostic performance in HAND frontal cortex (AUC = 0.771, 95% CI: 0.724–0.818). FOXO3 expression positively correlated with APP (R = 0.558). FOXO3 expression negatively correlated with MAPT (R = −0.690) and SORL1 (R = −0.856). ACE showed strong positive correlation with FOXO3 (R = 0.685), suggesting vascular involvement. STAT3 and ZNF341 were identified from 21 transcription factor candidates. STAT3 ranked first in HAND integrated cohort (n = 107, AUC = 0.759). STAT3 may function as an inflammatory mediator through JAK-STAT signaling. ZNF341 showed strongest transcriptional association with disease status (β = 5.09 in AD, β = 4.85 in HAND). The two-gene panel (FOXO3-ZNF341) achieved diagnostic accuracy in blood samples (AUC = 0.764, n = 329). This performance approaches clinical utility thresholds. Blood-based detection offers non-invasive diagnostic potential. Saturation analysis identified three molecules as optimal panel size. Marginal AUC gains declined below 0.02 beyond this threshold. FOXO3, STAT3, and ZNF341 showed stable selection frequency (97%, 65%, and 100%, respectively). PI3K-Akt and FoxO signaling pathways were enriched, which are known to regulate apoptosis and cell survival. Taken together, these computational findings indicate FOXO3 transcriptional regulatory activity in neurodegeneration. The three-molecule panel represents candidate blood-based diagnostic biomarkers. These candidate biomarkers warrant further investigation in independent clinical cohorts.

Read PDF

Similar papers

Review Open access Sep 2026

MicroRNAs as Diagnostic Biomarkers for Alzheimer’s Disease and Related Dementias

This review delineates the critical functions of specific miRNAs in orchestrating the three primary pathological pillars of AD: amyloid-β (Aβ) buildup, chronic neuroinflammation, and systemic oxidative stress.

Manivannan Subramanian, Aditi Singh, Amit Singh · 0 citations
Open access Aug 2026

Peripheral blood microarray-based transcriptomic and epigenetic analyses identify immune, inflammation, and metabolic dysregulation in Alzheimer’s disease

Leveraging multi-omics to better understand the molecular signatures and pathways underlying Alzheimer’s disease (AD) pathogenesis is critical for early diagnosis and disease modifying interventions. We performed peripheral blood transcriptome (N = 669) and epigenome microarray analyses (N = 553) on non-Hispanic white...

Brendan A. Mitchell, I. Hausle, Sarah Smith et al. · 0 citations
Open access Aug 2026

Transcriptomic Signatures of Microglial Phagocytosis Reveal Diagnostic Markers and Immune Landscape in Alzheimer's Disease

This study identified five core signature genes that form a highly accurate diagnostic model validated in independent cohorts and identified two molecular subtypes with distinct immune features, constructed regulatory networks, and predicted potential therapeutics including Tamibarotene.

Hui-Min Chang, Yun Liu, Xiao-Jun Yang et al. · 0 citations
Review Aug 2026

Emerging diagnostic biomarkers and therapeutic targets in Alzheimer's disease

A combination of biomarker-guided diagnostics with mechanism-based therapies might enable precision medicine approaches and improve clinical outcomes in AD.

Thumbar Kishan Dineshbhai, Dhvani Rafaliya, Aditya Singh et al. · 1 citation
Open access Aug 2026

Translating peripheral blood biomarkers into Alzheimer’s disease care: an exploratory dual-pathway model of immune and viral dynamics in behavioral and psychological symptoms of dementia

Background Behavioral and psychological symptoms of dementia (BPSD) critically complicate Alzheimer’s disease care, yet the precise biological correlates for highly heterogeneous symptom domains remain largely unexplored. Objective To investigate an exploratory “dual-pathway framework” to map how macroscopic immunosene...

Ching-Tse Wu, Shuo-Peng Chou, Chuang-Rung Chang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.